Aspira Pathlab & Diagnostics Ltd - 540788 - Financial Results For The Quarter Ended September 30, 2022
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform that Board of Directors of the Company, in their meeting held today i.e. November 12, 2022 has inter-alia considered and approved the unaudited Financial Results for the quarter and half year ended on September 30, 2022. Aspira Pathlab & Diagnostics Ltd - 540788 - Financial Results For The Quarter Ended September 30, 2022
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform that Board of Directors of the Company, in their meeting held today i.e. November 12, 2022 has inter-alia considered and approved the unaudited Financial Results for the quarter and half year ended on September 30, 2022. Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 12, 2022
Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Saturday, 12th November, 2022 which was commenced at 03:30 P.M. and concluded at 04:30 PM. Attached Agenda items were approved in the meeting. Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for The Meeting Of Board Of Directors Of The Company To Be Held On 12Th November, 2022.
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 ,inter alia, to consider and approve the unaudited financial results for the quarter and half year ended 30th September, 2022 and other business matters Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Priya PandeyDesignation :- Company Secretary and Compliance Officer Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, for the quarter ended 30th September, 2022, as received from Link Intime India Pvt. Ltd, the Registrar and Share Transfer Agent (RTA) of the Company. Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Please find attached disclosure in Form - C from Yashraj Biotechnology Limited, Promoter pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Yashraj Biotechnology Ltd Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nikunj Velji Mange Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the code of Prohibition of Insider Trading adopted by Company, the trading window for dealing in securities of the company will remain closed from October 01, 2022, till 48 hours after declaration of Financial Results of the Company for the quarter ended September 30, 2022.